Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABIO Nasdaq 2834 http://arcabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arca Biopharma Inc

ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium - Sep 12th, 2019 12:30 pm
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting - Sep 11th, 2019 12:30 pm
Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful? - Sep 4th, 2019 5:37 pm
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update - Aug 1st, 2019 8:30 pm
One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price - Jun 4th, 2019 11:09 am
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure - May 13th, 2019 1:00 pm
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update - May 8th, 2019 8:30 pm
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure - May 1st, 2019 12:30 pm
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial - Apr 23rd, 2019 12:30 pm
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology - Mar 18th, 2019 12:30 pm
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine - Mar 6th, 2019 1:00 pm
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update - Feb 27th, 2019 9:15 pm
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug - Feb 20th, 2019 12:30 pm
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors - Jan 16th, 2019 1:30 pm
ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling - Dec 26th, 2018 4:47 pm
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial - Dec 20th, 2018 9:01 pm
ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update - Nov 14th, 2018 9:30 pm
GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions - Nov 12th, 2018 1:30 pm
ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions - Nov 5th, 2018 1:30 pm